+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Acute Kidney Injury Treatment Market (AKI) by Product (Dialysis, Drug Therapy), Injury Type (Intrinsic-Renal Acute Kidney Injury, Post-Renal Acute Kidney Injury, Pre-Renal Acute Kidney Injury), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888853
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Acute Kidney Injury Treatment Market size was estimated at USD 1.87 billion in 2023, USD 2.02 billion in 2024, and is expected to grow at a CAGR of 7.81% to reach USD 3.17 billion by 2030.

Acute kidney injury (AKI) treatment refers to the provision of therapeutic solutions, devices, and services for the management and recovery of patients suffering from acute kidney injury, a sudden case of kidney damage or failure. Treatment options include various pharmaceutical drugs, dialysis equipment, advanced treatment modalities, and supportive care services aimed at restoring normal kidney function and preventing further complications. The application of AKI treatment encompasses various clinical settings such as hospitals, intensive care units (ICUs), nephrology clinics, and home healthcare. The increasing prevalence of conditions leading to AKI and a growing elderly population vulnerable to AKI have necessitated the deployment of immediate treatment solutions. Additionally, technological advancements in diagnostic tools, therapies and rising healthcare expenditure have expanded the provision of treatment services. However, the lack of reimbursements for treatment options and the high cost of availing treatment for AKI may limit the accessibility of treatment options. Stringent regulatory policies leading to longer approval times and delayed commercialization of new products also pose concerns. However, manufacturers and biotechnological companies are exploring options to ease the regulatory approval process. It is crucial for businesses operating in this segment to invest in research and development with a focus on innovation.

Regional Insights

In the Americas, the United States is associated with advanced technological innovations that cater to the aging population with an increased risk of kidney diseases. The Americas region is characterized by the presence of government initiatives to expand AKI treatment options. The European Union witnesses a consistent need for novel AKI treatments due to increasing occurrences of CKD among its citizens. European nations, including Germany, France, and the UK, have robust biotechnology and pharmaceutical companies that are constantly innovating and exploring novel treatment options. China, Japan, and India have a significant need for AKI treatment owing to their large population base and increasing prevalence of kidney-related disorders. The Chinese government has launched several initiatives to enhance healthcare access, which, in turn, is expected to boost the demand for AKI treatments. Japan also exhibits a significant market potential due to its rapidly aging population and advanced healthcare infrastructure.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Kidney Injury Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Kidney Injury Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Kidney Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alloksys Life Sciences B.V., Amgen Inc., Angion Biomedica Corp., Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Bayer AG, bioMérieux SA, Dr. Reddys Laboratories Ltd., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Reata Pharmaceuticals Inc. by Biogen Inc., Rockwell Medical, Inc., Silver Creek Pharmaceuticals, Inc., Stealth BioTherapeutics, Inc., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Acute Kidney Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Dialysis
      • Continuous Renal Replacement Therapy (CRRT)
      • Intermittent Hemodialysis
      • Sustained Low-Efficiency Dialysis (SLED)
    • Drug Therapy
      • Antibiotics
      • Diuretics
      • Immunosuppressive Agents
  • Injury Type
    • Intrinsic-Renal Acute Kidney Injury
    • Post-Renal Acute Kidney Injury
    • Pre-Renal Acute Kidney Injury
  • End-User
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Acute Kidney Injury Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Kidney Injury Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Acute Kidney Injury Treatment Market?
  4. What is the market share of the leading vendors in the Acute Kidney Injury Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Acute Kidney Injury Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Acute Kidney Injury Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of kidney failures and kidney-related diseases
5.1.1.2. Growing number of drug approvals for the treatment of kidney disorders
5.1.1.3. Government initiatives to raise awareness about kidney health
5.1.2. Restraints
5.1.2.1. High cost of availing treatment and lack of reimbursements
5.1.3. Opportunities
5.1.3.1. Advancements to enhance kidney treatment options and improve disease detection
5.1.3.2. New hospitals providing kidney treatment and improvements in outpatient care
5.1.4. Challenges
5.1.4.1. Stringent regulations concerning certain kidney injury treatment options
5.2. Market Segmentation Analysis
5.2.1. Product: Rising number of research initiatives to improve dialysis treatment
5.2.2. Injury type: Awareness about underlying causes of kidney injury leading to the creation of treatments for Intrinsic-Renal Acute Kidney Injury
5.2.3. End-user: Improvements in outpatient care leading to rising prevalence of ambulatory surgical centers (ASCs)
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Acute Kidney Injury Treatment Market, by Product
6.1. Introduction
6.2. Dialysis
6.3.1. Continuous Renal Replacement Therapy (CRRT)
6.3.2. Intermittent Hemodialysis
6.3.3. Sustained Low-Efficiency Dialysis (SLED)
6.3. Drug Therapy
6.4.1. Antibiotics
6.4.2. Diuretics
6.4.3. Immunosuppressive Agents
7. Acute Kidney Injury Treatment Market, by Injury Type
7.1. Introduction
7.2. Intrinsic-Renal Acute Kidney Injury
7.3. Post-Renal Acute Kidney Injury
7.4. Pre-Renal Acute Kidney Injury
8. Acute Kidney Injury Treatment Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
9. Americas Acute Kidney Injury Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Acute Kidney Injury Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Acute Kidney Injury Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Novartis to Buy Chinook for Up to USD 3.5 Billion, Expanding Kidney Disease Pipeline
12.3.1.2. CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
12.3.2. Award, Recognition, & Expansion
12.3.2.1. SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Alloksys Life Sciences B.V.
13.1.3. Amgen Inc.
13.1.4. Angion Biomedica Corp.
13.1.5. Asahi Kasei Medical Co., Ltd.
13.1.6. B. Braun Melsungen AG
13.1.7. Baxter International, Inc.
13.1.8. Bayer AG
13.1.9. bioMérieux SA
13.1.10. Dr. Reddys Laboratories Ltd.
13.1.11. Fresenius Medical Care AG & Co. KGaA
13.1.12. GlaxoSmithKline PLC
13.1.13. Johnson & Johnson Services, Inc.
13.1.14. Merck & Co., Inc.
13.1.15. Novartis AG
13.1.16. Otsuka Pharmaceutical Co., Ltd.
13.1.17. Pfizer Inc.
13.1.18. Reata Pharmaceuticals Inc. by Biogen Inc.
13.1.19. Rockwell Medical, Inc.
13.1.20. Silver Creek Pharmaceuticals, Inc.
13.1.21. Stealth BioTherapeutics, Inc.
13.1.22. Teva Pharmaceutical Industries Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ACUTE KIDNEY INJURY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ACUTE KIDNEY INJURY TREATMENT MARKET DYNAMICS
FIGURE 7. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2023 VS 2030 (%)
FIGURE 10. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Abbott Laboratories
  • Alloksys Life Sciences B.V.
  • Amgen Inc.
  • Angion Biomedica Corp.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Bayer AG
  • bioMérieux SA
  • Dr. Reddys Laboratories Ltd.
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Reata Pharmaceuticals Inc. by Biogen Inc.
  • Rockwell Medical, Inc.
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth BioTherapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information